Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

5.33USD
23 May 2018
Change (% chg)

$0.13 (+2.50%)
Prev Close
$5.20
Open
$5.22
Day's High
$5.52
Day's Low
$5.22
Volume
163,662
Avg. Vol
252,156
52-wk High
$19.30
52-wk Low
$3.76

Chart for

About

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $193.26
Shares Outstanding(Mil.): 37.17
Dividend: --
Yield (%): --

Financials

  NLNK.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -2.13 -- --
ROI: -52.12 -7.38 12.74
ROE: -55.08 -10.11 14.64

BRIEF-Newlink Genetics Corp Reports Qtrly Loss Per Share Of $0.49

* NEWLINK GENETICS CORP QTRLY BASIC AND DILUTED LOSS PER SHARE $0.49

May 03 2018

BRIEF-Newlink Genetics Appoints Matthew Sherman To Board

* NEWLINK GENETICS - IN CONNECTION WITH APPOINTMENT OF MATTHEW SHERMAN TO CO'S BOARD, BOARD WILL BE COMPRISED OF EIGHT DIRECTORS Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Newlink Genetics Reviews Clinical Programs

* IN LIGHT OF INCYTE'S ANNOUNCEMENT REGARDING ECHO-301 TRIAL, CO UNDERTAKING REVIEW OF CLINICAL PROGRAMS Source text for Eikon: Further company coverage:

Apr 06 2018

BRIEF-NewLink Genetics, Cantor Fitzgerald Enter Controlled Equity Offering Sales Agreement

* NEWLINK GENETICS SAYS ON MARCH 12, CO ENTERED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING

Mar 13 2018

BRIEF-NewLink Genetics Qtrly Loss Per Share $0.37

* NEWLINK GENETICS REPORTS FOURTH QUARTER, YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES UPDATE FOR INDOXIMOD PROGRAMS

Mar 01 2018

BRIEF-Newlink Genetics Outlines 2018 Business Priorities

* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS

Jan 08 2018

BRIEF-Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement

* NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014

Dec 11 2017

Competitors

Earnings vs. Estimates